A new drug combination shows unexpected synergy against liver fibrosis. A new study reveals that using two drugs together produces a much stronger effect than using either one alone, suggesting a ...
The utilization of biodegradable biomaterials as a therapeutic modality for musculoskeletal tissue regeneration has emerged as a promising avenue for ...
New human clinical trial proves arginine, an amino acid, can modify plaque formation on teeth, thereby protecting ...
The Alpestria-1 study enrolled (in France, USA and Spain) 26 patients with Alport syndrome at high risk of a rapid loss of kidney function despite stable multiple SoC drugs, including ...
FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Approval from HREC for Phase 1/2 Diabetic Foot Ulcer Trial In ...
UK biotech Engitix has raised a $25 million series A extension from existing investor Netherton Investments, investing on behalf of BlueCrest Capital Management co-founder Mike Platt. The funding will ...
AZoLifeSciences on MSN
Turning human fat into insulin-producing organoids that reverse diabetes
By preserving fat tissue architecture, researchers created organoids that restore insulin function, paving the way for ...
Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted ...
Engitix plans to use the funds for preclinical development across its pipeline in solid tumors and fibrosis, and to expand ...
When a person suffers a stroke, physicians must restore blood flow to the brain as quickly as possible to save their life.
"After a review of BIASURGE®, Vizient’s client-led council agreed this technology offers a unique benefit over other products ...
Injectable filler could help breast cancer patients avoid complex reconstruction procedures, though human trials are still needed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback